A Market Entry With an Expiry Date Written Into It.
EUA strategy under Section 564 — authorization while a declared emergency lasts, and the transition plan that decides whether your product survives the day it ends.
Four Conditions Must All Be True. FDA Checks Them in Order.
An EUA is not a faster review of the ordinary standard. It is a different standard, available only inside a declared emergency — and it fails on any one of these.
A Declaration Exists
The Secretary of HHS has declared circumstances justifying emergency use for the agent or threat in question. Without it, there is no authority to authorize anything.
A Serious Threat
The agent can cause a serious or life-threatening disease or condition — the risk side of the balance FDA will strike.
“May Be Effective”
The evidence bar, and the phrase that defines the pathway. Lower than “effective” — and still evidence, still weighed against known and potential risks.
No Adequate Alternative
No approved, available alternative that is adequate. An approval elsewhere in the space can close this gate on you.
And then the declaration ends.
An EUA terminates with the declaration that supports it. Products that planned for that day transitioned to a 510(k), De Novo, NDA, or BLA before it arrived; products that didn’t left the market. The transition strategy is not a post-script to an EUA program — it is the reason to run one properly.
Speed Now, Obligations Throughout, an Ending You Must Plan.
The EUA trade is explicit. FDA authorizes on “may be effective” evidence, and in exchange the authorization carries conditions that run for its whole life: fact sheets for providers and recipients, adverse-event reporting, records and access, distribution controls, and often a commitment to keep generating data. Every condition is enforceable, and every one is a compliance program you must staff.
It also runs on a clock nobody in your company controls. The most expensive EUA mistake isn’t the application — it’s the company that treats authorization as arrival and finds itself, when the declaration lapses, holding inventory it cannot legally ship and a marketing application it never started.
The distinction shapes labeling, promotion, liability, and procurement — and it must be visible in everything the product says about itself.
Six Disciplines That Carry an EUA.
Emergency speed only works on top of ordinary rigor — assembled faster.
Eligibility & Evidence Assessment
The honest read on whether the four conditions are met and whether your data clears “may be effective” — before an emergency timeline consumes the team.
Request Preparation
The EUA request built at emergency pace without emergency sloppiness: the evidence summary, risk-benefit analysis, and manufacturing information FDA needs to act.
Authorized Labeling
Fact sheets for healthcare providers and recipients, plus the “authorized, not approved” language that must appear consistently everywhere the product speaks.
Condition Compliance Systems
Adverse-event reporting, records and access, distribution tracking — each authorization condition operationalized as a real, staffed process.
Transition Strategy
The marketing-application plan built on day one: which pathway, which evidence gaps, and what has to be true before the declaration ends.
Amendments & Reissuance
Authorizations change — new indications, new data, revised fact sheets. Each amendment managed as the regulatory action it is.
Reporting, records, and distribution controls run for the authorization’s whole life — each one a staffed process, not a promise.
Authorization Is a Lease, Not a Title.
An EUA can be revised or revoked when the science, the alternatives, or the declaration changes. That is not a defect in the pathway — it is the pathway. Section 564 buys you a market while a crisis lasts, on evidence that would not otherwise support one.
Which is why we run every EUA with two dates on the wall: the day it is granted, and the day it ends. The second one is only a surprise to companies that never planned the transition to 510(k), De Novo, or BLA.
Six Failure Modes We Are Brought In to Prevent.
Emergency conditions make each of these easier to commit and more expensive to carry.
Authorization mistaken for approval
Promotion, pricing, and procurement conversations that read as though the product is approved — the fastest route to an untitled letter during an emergency.
No transition plan
The declaration ends on a schedule set in Washington. A company with no marketing application in progress loses the market it just built.
Conditions unstaffed
Reporting and record-keeping obligations assigned to whoever is free — and unmet by the time FDA asks for the file.
Fact sheets that drift
Provider and recipient materials that no longer match the authorization after two amendments — each version still in the field.
Manufacturing scaled past the file
Emergency demand met with process changes the authorization never described — and a quality system that cannot show the product shipped is the product authorized.
Data that stops when the crisis peaks
The evidence generation FDA expected to continue, quietly deprioritized — leaving the eventual marketing application no stronger than the EUA was.
Emergency Regulatory Leadership That Plans for the Ending.
Our leads have built authorization requests, run condition-compliance programs, and taken authorized products onto permanent pathways.
“Every EUA has two dates that matter: the day it’s granted, and the day it ends. Only one of them is a surprise to unprepared companies.”
The discipline we bring to emergency programs.
Holding an EUA — or Seeking One? Plan the Transition Now.
A senior lead can assess eligibility, staff the conditions, and map the permanent pathway before the declaration decides your timeline for you.
Senior-led. Embedded in your team. No junior hand-offs.